Cagrilintide/semaglutide, marketed as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist. Type II diabetes treatment.
CagriSema is under investigation to treat type 2 diabetes and obesity. Preliminary trial results found a greater weight loss compared to either semaglutide or cagrilintide alone. HbA1c was significantly improved compared to cagrilintide alone and non-significantly better than semaglutide alone.In a Phase II trial, weight loss averaged -15.6 percent after 32 weeks, comparable in efficacy to tirzepatide.
CagriSema entered Phase III clinical trials in 2023. the drug was associated with an average 15.1% weight loss over 12 weeks.
Product Display

Customer feedback

Factory Introduction


Packaging and transportation


Our Advantages
High quality, competitive price, adequate stock and fast delivery competitive price.
Enterprise standard and 99% purity.
We are manufacturer and can provide high quality products with factory price.
Safe and fast delivery
1)Parcel can be sent out in 3 working days after payment. tracking number available.
2)Secure and discreet shipment. various transportation methods for your choice.
3)Customs pass rate 99%
FAQ
Hot Tags: cagrisema 5+5mg 10+10mg compound 10 vials powder, China cagrisema 5+5mg 10+10mg compound 10 vials powder manufacturers, suppliers, factory, best peptide for cutting, tirzepatide GLP 1, get tirzepatide online, peptide for appetite suppressant, peptide tirzepatide, semaglutide compounding pharmacy cost






